{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:10:19Z","timestamp":1793736619697,"version":"4.6.1"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T00:00:00Z","timestamp":1499904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001721","name":"University of Groningen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s11897-017-0343-y","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T23:54:21Z","timestamp":1499903661000},"page":"235-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":284,"title":["From Inflammation to Fibrosis\u2014Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities"],"prefix":"10.1007","volume":"14","author":[{"given":"Navin","family":"Suthahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman H.W.","family":"Sillj\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"key":"343_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","volume":"8","author":"AL Bui","year":"2011","unstructured":"Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30\u201341. doi:\n10.1038\/nrcardio.2010.165\n\n.","journal-title":"Nat Rev Cardiol"},{"key":"343_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271\u201389. doi:\n10.3322\/caac.21349\n\n.","journal-title":"CA Cancer J Clin"},{"key":"343_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cardfail.2010.08.010","volume":"17","author":"G Giamouzis","year":"2011","unstructured":"Giamouzis G, Kalogeropoulos A, Georgiopoulou V, Laskar S, Smith AL, Dunbar S, et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail. 2011;17:54\u201375. doi:\n10.1016\/j.cardfail.2010.08.010\n\n.","journal-title":"J Card Fail"},{"key":"343_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","volume":"71","author":"P Kong","year":"2014","unstructured":"Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71:549\u201374. doi:\n10.1007\/s00018-013-1349-6\n\n.","journal-title":"Cell Mol Life Sci"},{"key":"343_CR5","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1038\/ki.2010.418","volume":"100","author":"SB Lee","year":"2010","unstructured":"Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl. 2010;100:S22\u20136. doi:\n10.1038\/ki.2010.418\n\n.","journal-title":"Kidney Int Suppl"},{"key":"343_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1096\/fj.06-7227rev","volume":"21","author":"CN Serhan","year":"2007","unstructured":"Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O\u2019Neill LAJ, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007;21:325\u201332. doi:\n10.1096\/fj.06-7227rev\n\n.","journal-title":"FASEB J"},{"key":"343_CR7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028\u201340. doi:\n10.1038\/nm.2807\n\n.","journal-title":"Nat Med"},{"key":"343_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF01986484","volume":"3","author":"DL Wilhelm","year":"1973","unstructured":"Wilhelm DL. Mechanisms responsible for increased vascular permeability in acute inflammation. Agents Actions. 1973;3:297\u2013306. doi:\n10.1007\/BF01986484\n\n.","journal-title":"Agents Actions"},{"key":"343_CR9","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/art.24625","volume":"60","author":"W Zheng","year":"2009","unstructured":"Zheng W, Li R, Pan H, He D, Xu R, Guo TB, et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum. 2009;60:1957\u201365. doi:\n10.1002\/art.24625\n\n.","journal-title":"Arthritis Rheum"},{"key":"343_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.matbio.2014.01.015","volume":"35","author":"TN Wight","year":"2014","unstructured":"Wight TN, Kang I, Merrilees MJ. Versican and the control of inflammation. Matrix Biol. 2014;35:152\u201361. doi:\n10.1016\/j.matbio.2014.01.015\n\n.","journal-title":"Matrix Biol"},{"key":"343_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fimmu.2014.00101","volume":"5","author":"AC Petrey","year":"2014","unstructured":"Petrey AC, de la Motte CA. Hyaluronan, a crucial regulator of inflammation. Front Immunol. 2014;5:101. doi:\n10.3389\/fimmu.2014.00101\n\n.","journal-title":"Front Immunol"},{"key":"343_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0014-5793(99)00731-0","volume":"453","author":"A Neumann","year":"1999","unstructured":"Neumann A, Schinzel R, Palm D, Riederer P, M\u00fcnch G. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett. 1999;453:283\u20137. doi:\n10.1016\/S0014-5793(99)00731-0\n\n.","journal-title":"FEBS Lett"},{"key":"343_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1124\/dmd.107.016501.CYP3A4-Mediated","volume":"28","author":"M Litwiniuk","year":"2016","unstructured":"Litwiniuk M, Krejner A, Speyrer MS, Gauto AR, Grzela T. Hyaluronic acid in inflammation and tissue regeneration. Wounds a Compend Clin Res Pract. 2016;28:78\u201388. doi:\n10.1124\/dmd.107.016501.CYP3A4-Mediated\n\n.","journal-title":"Wounds a Compend Clin Res Pract"},{"key":"343_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1021\/acsbiomaterials.5b00181","volume":"1","author":"JE Rayahin","year":"2015","unstructured":"Rayahin JE, Buhrman JS, Zhang Y, Koh TJ, Gemeinhart RA. High and low molecular weight hyaluronic acid differentially influence macrophage activation. ACS Biomater Sci Eng. 2015;1:481\u201393. doi:\n10.1021\/acsbiomaterials.5b00181\n\n.","journal-title":"ACS Biomater Sci Eng"},{"key":"343_CR15","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Ortega-G\u00f3mez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med. 2013;5:661\u201374. doi:\n10.1002\/emmm.201202382\n\n. Authoritative review on the resolution of inflammation and its consequences, including the development of fibrosis.","DOI":"10.1002\/emmm.201202382"},{"key":"343_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.smim.2015.03.004","volume":"27","author":"CN Serhan","year":"2015","unstructured":"Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015;27:200\u201315. doi:\n10.1016\/j.smim.2015.03.004\n\n.","journal-title":"Semin Immunol"},{"key":"343_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2014.02.009","volume":"40","author":"CD Buckley","year":"2014","unstructured":"Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014;40:315\u201327. doi:\n10.1016\/j.immuni.2014.02.009\n\n.","journal-title":"Immunity"},{"key":"343_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1471-4906(03)00139-X","volume":"24","author":"T Fukao","year":"2003","unstructured":"Fukao T, Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol. 2003;24:358\u201363. doi:\n10.1016\/S1471-4906(03)00139-X\n\n.","journal-title":"Trends Immunol"},{"key":"343_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nri1630","volume":"5","author":"FY Liew","year":"2005","unstructured":"Liew FY, Xu D, Brint EK, O\u2019Neill LAJ. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005;5:446\u201358. doi:\n10.1038\/nri1630\n\n.","journal-title":"Nat Rev Immunol"},{"key":"343_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fimmu.2012.00071","volume":"3","author":"S Ueha","year":"2012","unstructured":"Ueha S, Shand FHW, Matsushima K. Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis. Front Immunol. 2012;3:71. doi:\n10.3389\/fimmu.2012.00071\n\n.","journal-title":"Front Immunol"},{"key":"343_CR21","doi-asserted-by":"publisher","unstructured":"Bochaton-Piallat M-L, Gabbiani G, Hinz B. The myofibroblast in wound healing and fibrosis: answered and unanswered questions. F1000Research 2016;5:752\u201325. doi:\n10.12688\/f1000research.8190.1\n\n.","DOI":"10.12688\/f1000research.8190.1"},{"key":"343_CR22","doi-asserted-by":"publisher","unstructured":"\u2022 Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010;225:631\u20137. doi:\n10.1002\/jcp.22322\n\n. State-of-the-art review on the central role of the cardiac fibroblast in cardiac fibrosis.","DOI":"10.1002\/jcp.22322"},{"key":"343_CR23","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1161\/ATVBAHA.108.173898","volume":"28","author":"AC Newby","year":"2008","unstructured":"Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008;28:2108\u201314. doi:\n10.1161\/ATVBAHA.108.173898\n\n.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"343_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00281-016-0555-3","volume":"38","author":"AM Grabiec","year":"2016","unstructured":"Grabiec AM, Hussell T. The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation. Semin Immunopathol. 2016;38:409\u201323. doi:\n10.1007\/s00281-016-0555-3\n\n.","journal-title":"Semin Immunopathol"},{"key":"343_CR25","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1128\/IAI.02194-14","volume":"82","author":"FT Oliveira de","year":"2014","unstructured":"de Oliveira FT, Andrade PR, de Mattos Barbosa MG, Pinto TGT, Ferreira PF, Ferreira H, et al. Effect of apoptotic cell recognition on macrophage polarization and mycobacterial persistence. Infect Immun. 2014;82:3968\u201378. doi:\n10.1128\/IAI.02194-14\n\n.","journal-title":"Infect Immun"},{"key":"343_CR26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1172\/JCI1112","volume":"101","author":"VA Fadok","year":"1998","unstructured":"Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine\/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101:890\u20138. doi:\n10.1172\/JCI1112\n\n.","journal-title":"J Clin Invest"},{"key":"343_CR27","doi-asserted-by":"publisher","unstructured":"\u2022 MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008;180:2650\u20138. doi:\n10.4049\/jimmunol.180.4.2650\n\n. First description of the role of the pro-fibrotic protein galectin-3 on macrophage maturation towards the alternative phenotype.","DOI":"10.4049\/jimmunol.180.4.2650"},{"key":"343_CR28","doi-asserted-by":"publisher","unstructured":"\u2022 Gong D, Shi W, Yi S, Chen H, Groffen J, Heisterkamp N. TGF\u03b2 signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 2012;13:31. doi:\n10.1186\/1471-2172-13-31\n\n. The quintessential fibrosis factor TGF-\u03b2 is described as a player in alternative macrophage activation.","DOI":"10.1186\/1471-2172-13-31"},{"key":"343_CR29","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1083\/jcb.201301081","volume":"202","author":"DH Madsen","year":"2013","unstructured":"Madsen DH, Leonard D, Masedunskas A, Moyer A, J\u00fcrgensen HJ, Peters DE, et al. M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway. J Cell Biol. 2013;202:951\u201366. doi:\n10.1083\/jcb.201301081\n\n.","journal-title":"J Cell Biol"},{"key":"343_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/cvr\/cvu062","volume":"102","author":"S Linthout Van","year":"2014","unstructured":"Van Linthout S, Miteva K, Tsch\u00f6pe C. Crosstalk between fibroblasts and inflammatory cells. Cardiovasc Res. 2014;102:258\u201369. doi:\n10.1093\/cvr\/cvu062\n\n.","journal-title":"Cardiovasc Res"},{"key":"343_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cvr\/cvt100","volume":"99","author":"B L\u00f3pez","year":"2013","unstructured":"L\u00f3pez B, Gonz\u00e1lez A, Lindner D, Westermann D, Ravassa S, Beaumont J, et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc Res. 2013;99:111\u201320. doi:\n10.1093\/cvr\/cvt100\n\n.","journal-title":"Cardiovasc Res"},{"key":"343_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1359-6101(99)00029-5","volume":"11","author":"JE Murphy-Ullrich","year":"2000","unstructured":"Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000;11:59\u201369. doi:\n10.1016\/S1359-6101(99)00029-5\n\n.","journal-title":"Cytokine Growth Factor Rev"},{"key":"343_CR33","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1042\/BST0361472","volume":"36","author":"OB Garner","year":"2008","unstructured":"Garner OB, Baum LG. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem Soc Trans. 2008;36:1472\u20137. doi:\n10.1042\/BST0361472\n\n.","journal-title":"Biochem Soc Trans"},{"key":"343_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10741-006-9196-2","volume":"11","author":"A Yndestad","year":"2006","unstructured":"Yndestad A, Dam\u00e5s JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure\u2014the whys and wherefores. Heart Fail Rev. 2006;11:83\u201392. doi:\n10.1007\/s10741-006-9196-2\n\n.","journal-title":"Heart Fail Rev"},{"key":"343_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nri3800","volume":"15","author":"S Epelman","year":"2015","unstructured":"Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol. 2015;15:117\u201329. doi:\n10.1038\/nri3800\n\n.","journal-title":"Nat Rev Immunol"},{"key":"343_CR36","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.imbio.2011.06.009","volume":"217","author":"JG Barin","year":"2012","unstructured":"Barin JG, Rose NR, Cih\u00e1kov\u00e1 D. Macrophage diversity in cardiac inflammation: a review. Immunobiology. 2012;217:468\u201375. doi:\n10.1016\/j.imbio.2011.06.009\n\n.","journal-title":"Immunobiology"},{"key":"343_CR37","doi-asserted-by":"publisher","first-page":"e35144","DOI":"10.1371\/journal.pone.0035144","volume":"7","author":"F Ma","year":"2012","unstructured":"Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF \u03b2\/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One. 2012;7:e35144. doi:\n10.1371\/journal.pone.0035144\n\n.","journal-title":"PLoS One"},{"key":"343_CR38","doi-asserted-by":"publisher","unstructured":"Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014;6:13. doi:\n10.12703\/P6-13\n\n.","DOI":"10.12703\/P6-13"},{"key":"343_CR39","doi-asserted-by":"publisher","unstructured":"\u2022 Aoyagi T, Matsui T. The cardiomyocyte as a source of cytokines in cardiac injury. J Cell Sci Ther. 2012;2011:130\u20134. doi:\n10.1016\/j.pestbp.2011.02.012.Investigations\n\n. Summary of heart as a secreting organ for inflammatory cytokines.","DOI":"10.1016\/j.pestbp.2011.02.012.Investigations"},{"key":"343_CR40","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.yjmcc.2012.10.002","volume":"53","author":"X Yu","year":"2012","unstructured":"Yu X, Deng L, Wang D, Li N, Chen X, Cheng X, et al. Mechanism of TNF-\u03b1 autocrine effects in hypoxic cardiomyocytes: initiated by hypoxia inducible factor 1\u03b1, presented by exosomes. J Mol Cell Cardiol. 2012;53:848\u201357. doi:\n10.1016\/j.yjmcc.2012.10.002\n\n.","journal-title":"J Mol Cell Cardiol"},{"key":"343_CR41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1023\/A:1011401825680","volume":"6","author":"KC Wollert","year":"2001","unstructured":"Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95\u2013103. doi:\n10.1023\/A:1011401825680\n\n.","journal-title":"Heart Fail Rev"},{"key":"343_CR42","doi-asserted-by":"publisher","unstructured":"Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006;8 Suppl 2:S3. doi:\n10.1186\/ar1917\n\n.","DOI":"10.1186\/ar1917"},{"key":"343_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cardiores.2007.06.003","volume":"76","author":"NA Turner","year":"2007","unstructured":"Turner NA, Mughal RS, Warburton P, O\u2019Regan DJ, Ball SG, Porter KE. Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res. 2007;76:81\u201390. doi:\n10.1016\/j.cardiores.2007.06.003\n\n.","journal-title":"Cardiovasc Res"},{"key":"343_CR44","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Lindner D, Zietsch C, Tank J, Sossalla S, Fluschnik N, Hinrichs S, et al. Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res Cardiol. 2014;109:428. doi:\n10.1007\/s00395-014-0428-7\n\n. State-of-the-art review on the central role of the cardiac fibroblast in cardiac inflammation.","DOI":"10.1007\/s00395-014-0428-7"},{"key":"343_CR45","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1084\/jem.20132126","volume":"211","author":"L Wu","year":"2014","unstructured":"Wu L, Ong S, Talor MV, Barin JG, Baldeviano GC, Kass DA, et al. Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med. 2014;211:1449\u201364. doi:\n10.1084\/jem.20132126\n\n.","journal-title":"J Exp Med"},{"key":"343_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.biocel.2009.10.010","volume":"42","author":"C Ospelt","year":"2010","unstructured":"Ospelt C, Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol. 2010;42:495\u2013505. doi:\n10.1016\/j.biocel.2009.10.010\n\n.","journal-title":"Int J Biochem Cell Biol"},{"key":"343_CR47","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Liu L, Wang Y, Cao Z-Y, Wang M-M, Liu X-M, Gao T, et al. Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. J Cell Mol Med. 2015;19:2728\u201340. doi:\n10.1111\/jcmm.12659\n\n. Important and interesting report on the emerging role of innate immunity and toll-like receptors in cardiac remodeling.","DOI":"10.1111\/jcmm.12659"},{"key":"343_CR48","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbadis.2012.11.017","volume":"2013","author":"P Huebener","year":"1832","unstructured":"Huebener P, Schwabe RF. Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim Biophys Acta. 1832;2013:1005\u201317. doi:\n10.1016\/j.bbadis.2012.11.017\n\n.","journal-title":"Biochim Biophys Acta"},{"key":"343_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.smim.2003.10.003","volume":"16","author":"K Takeda","year":"2004","unstructured":"Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16:3\u20139. doi:\n10.1016\/j.smim.2003.10.003\n\n.","journal-title":"Semin Immunol"},{"key":"343_CR50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1161\/CIRCRESAHA.111.243196","volume":"110","author":"M Coggins","year":"2012","unstructured":"Coggins M, Rosenzweig A. The fire within: cardiac inflammatory signaling in health and disease. Circ Res. 2012;110:116\u201325. doi:\n10.1161\/CIRCRESAHA.111.243196\n\n.","journal-title":"Circ Res"},{"key":"343_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10741-016-9536-9","volume":"21","author":"A Piek","year":"2016","unstructured":"Piek A, de Boer RA, Sillj\u00e9 HHW. The fibrosis-cell death axis in heart failure. Heart Fail Rev. 2016;21:199\u2013211. doi:\n10.1007\/s10741-016-9536-9\n\n.","journal-title":"Heart Fail Rev"},{"key":"343_CR52","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","volume":"118","author":"JG Travers","year":"2016","unstructured":"Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. Circ Res. 2016;118:1021\u201340. doi:\n10.1161\/CIRCRESAHA.115.306565\n\n.","journal-title":"Circ Res"},{"key":"343_CR53","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.trsl.2014.08.008","volume":"165","author":"K Tian","year":"2015","unstructured":"Tian K, Liu Z, Wang J, Xu S, You T, Liu P. Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor \u03baB signaling. Transl Res. 2015;165:374\u201386. doi:\n10.1016\/j.trsl.2014.08.008\n\n.","journal-title":"Transl Res"},{"key":"343_CR54","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Herum KM, Lunde IG, Skrbic B, Louch WE, Hasic A, Boye S, et al. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart. Cardiovasc Res. 2015;106:217\u201326. doi:\n10.1093\/cvr\/cvv002\n\n. The prominent role of proteoglycans and other ECM associated proteins is supported by this interesting article focusing on syndecan-4.","DOI":"10.1093\/cvr\/cvv002"},{"key":"343_CR55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.yjmcc.2014.01.013","volume":"70","author":"K Fujiu","year":"2014","unstructured":"Fujiu K, Nagai R. Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol. 2014;70:64\u201373. doi:\n10.1016\/j.yjmcc.2014.01.013\n\n.","journal-title":"J Mol Cell Cardiol"},{"key":"343_CR56","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/jcp.20307","volume":"204","author":"S Fredj","year":"2005","unstructured":"Fredj S, Bescond J, Louault C, Delwail A, Lecron J-C, Potreau D. Role of interleukin-6 in cardiomyocyte\/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. J Cell Physiol. 2005;204:428\u201336. doi:\n10.1002\/jcp.20307\n\n.","journal-title":"J Cell Physiol"},{"key":"343_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.yjmcc.2016.03.005","volume":"94","author":"J Pellman","year":"2016","unstructured":"Pellman J, Zhang J, Sheikh F. Myocyte-fibroblast communication in cardiac fibrosis and arrhythmias: mechanisms and model systems. J Mol Cell Cardiol. 2016;94:22\u201331. doi:\n10.1016\/j.yjmcc.2016.03.005\n\n.","journal-title":"J Mol Cell Cardiol"},{"key":"343_CR58","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.ajpath.2014.11.027","volume":"185","author":"A Falkenham","year":"2015","unstructured":"Falkenham A, de Antueno R, Rosin N, Betsch D, Lee TDG, Duncan R, et al. Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis. Am J Pathol. 2015;185:927\u201342. doi:\n10.1016\/j.ajpath.2014.11.027\n\n.","journal-title":"Am J Pathol"},{"key":"343_CR59","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res. 2004;95:637\u201344. doi:\n10.1161\/01.RES.0000141427.61023.f4\n\n. Heparin-associated proteins and urokinase have important effects in myocardial fibrosis.","DOI":"10.1161\/01.RES.0000141427.61023.f4"},{"key":"343_CR60","doi-asserted-by":"publisher","unstructured":"Carlson S, Helterline D, Asbe L, Dupras S, Minami E, Farris S, et al. Cardiac macrophages adopt profibrotic\/M2 phenotype in infarcted hearts: role of urokinase plasminogen activator. J Mol Cell Cardiol. 2016;128 doi:\n10.1016\/j.yjmcc.2016.05.016\n\n.","DOI":"10.1016\/j.yjmcc.2016.05.016"},{"key":"343_CR61","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.115.020143","volume":"133","author":"O Henri","year":"2016","unstructured":"Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-L\u00e9vy F, et al. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation. 2016;133:1484\u20131497; discussion 1497. doi:\n10.1161\/CIRCULATIONAHA.115.020143\n\n.","journal-title":"Circulation"},{"key":"343_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cvr\/cvq272","volume":"89","author":"SP Levick","year":"2011","unstructured":"Levick SP, Mel\u00e9ndez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res. 2011;89:12\u20139. doi:\n10.1093\/cvr\/cvq272\n\n.","journal-title":"Cardiovasc Res"},{"key":"343_CR63","doi-asserted-by":"publisher","unstructured":"Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertens (Dallas, Tex 1979) 2009;53:1041\u20137. doi:\n10.1161\/HYPERTENSIONAHA.108.123158\n\n.","DOI":"10.1161\/HYPERTENSIONAHA.108.123158"},{"key":"343_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/sj.mn.7800188","volume":"10","author":"RA Boer de","year":"2003","unstructured":"de Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation. 2003;10:113\u201326. doi:\n10.1038\/sj.mn.7800188\n\n.","journal-title":"Microcirculation"},{"key":"343_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jacc.2005.03.044","volume":"46","author":"P Meer van der","year":"2005","unstructured":"van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125\u201333. doi:\n10.1016\/j.jacc.2005.03.044\n\n.","journal-title":"J Am Coll Cardiol"},{"key":"343_CR66","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jacc.2005.01.043","volume":"45","author":"S Namiuchi","year":"2005","unstructured":"Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;45:1406\u201312. doi:\n10.1016\/j.jacc.2005.01.043\n\n.","journal-title":"J Am Coll Cardiol"},{"key":"343_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.115.001770","volume":"4","author":"R Gogiraju","year":"2015","unstructured":"Gogiraju R, Xu X, Bochenek ML, Steinbrecher JH, Lehnart SE, Wenzel P, et al. Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice. J Am Heart Assoc. 2015;4:1\u201322. doi:\n10.1161\/JAHA.115.001770\n\n.","journal-title":"J Am Heart Assoc"},{"key":"343_CR68","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/mt.2013.89","volume":"21","author":"M Meloni","year":"2013","unstructured":"Meloni M, Marchetti M, Garner K, Littlejohns B, Sala-Newby G, Xenophontos N, et al. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol Ther. 2013;21:1390\u2013402. doi:\n10.1038\/mt.2013.89\n\n.","journal-title":"Mol Ther"},{"key":"343_CR69","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCRESAHA.114.302533","volume":"114","author":"M Rienks","year":"2014","unstructured":"Rienks M, Papageorgiou A-P, Frangogiannis NG, Heymans S. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res. 2014;114:872\u201388. doi:\n10.1161\/CIRCRESAHA.114.302533\n\n.","journal-title":"Circ Res"},{"key":"343_CR70","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/bcpt.12026","volume":"112","author":"E Mustonen","year":"2013","unstructured":"Mustonen E, Ruskoaho H, Rys\u00e4 J. Thrombospondins, potential drug targets for cardiovascular diseases. Basic Clin Pharmacol Toxicol. 2013;112:4\u201312. doi:\n10.1111\/bcpt.12026\n\n.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"343_CR71","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1096\/fj.11-190728","volume":"26","author":"EG Frolova","year":"2012","unstructured":"Frolova EG, Sopko N, Blech L, Popovic ZB, Li J, Vasanji A, et al. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J. 2012;26:2363\u201373. doi:\n10.1096\/fj.11-190728\n\n.","journal-title":"FASEB J"},{"key":"343_CR72","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jjcc.2013.09.013","volume":"63","author":"S Zhao","year":"2014","unstructured":"Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S, et al. Periostin expression is upregulated and associated with myocardial fibrosis in human failing hearts. J Cardiol. 2014;63:373\u20138. doi:\n10.1016\/j.jjcc.2013.09.013\n\n.","journal-title":"J Cardiol"},{"key":"343_CR73","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/CIRCULATIONAHA.107.714147","volume":"117","author":"D Westermann","year":"2008","unstructured":"Westermann D, Mersmann J, Melchior A, Freudenberger T, Petrik C, Schaefer L, et al. Biglycan is required for adaptive remodeling after myocardial infarction. Circulation. 2008;117:1269\u201376. doi:\n10.1161\/CIRCULATIONAHA.107.714147\n\n.","journal-title":"Circulation"},{"key":"343_CR74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.yjmcc.2016.10.011","volume":"101","author":"N Beetz","year":"2016","unstructured":"Beetz N, Rommel C, Schnick T, Neumann E, Lother A, Monroy-Ordonez EB, et al. Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload. J Mol Cell Cardiol. 2016;101:145\u201355. doi:\n10.1016\/j.yjmcc.2016.10.011\n\n.","journal-title":"J Mol Cell Cardiol"},{"key":"343_CR75","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.healun.2006.10.005","volume":"26","author":"J Jahanyar","year":"2007","unstructured":"\u2022 Jahanyar J, Joyce DL, Southard RE, Loebe M, Noon GP, Koerner MM, et al. Decorin-mediated transforming growth factor-beta inhibition ameliorates adverse cardiac remodeling. J Heart Lung Transplant. 2007;26:34\u201340. doi:\n10.1016\/j.healun.2006.10.005\n\n. This article illustrates the antifibrotic properties of the extracellular matrix protein decorin in the heart.","journal-title":"J Heart Lung Transplant"},{"key":"343_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","volume":"7","author":"RA Boer de","year":"2010","unstructured":"de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7:1\u20138. doi:\n10.1007\/s11897-010-0004-x\n\n.","journal-title":"Curr Heart Fail Rep"},{"key":"343_CR77","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Yu L, Ruifrok WPT, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6:107\u201317. doi:\n10.1161\/CIRCHEARTFAILURE.112.971168\n\n. First article describing galectin-3 as a therapeutic target in heart failure and myocardial fibrosis.","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168"},{"key":"343_CR78","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1242\/jcs.151159","volume":"128","author":"IR Nabi","year":"2015","unstructured":"Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. J Cell Sci. 2015;128:2213\u20139. doi:\n10.1242\/jcs.151159\n\n.","journal-title":"J Cell Sci"},{"key":"343_CR79","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1021\/acs.biochem.6b00504","volume":"55","author":"ML Talaga","year":"2016","unstructured":"Talaga ML, Fan N, Fueri AL, Brown RK, Bandyopadhyay P, Dam TK. Multitasking human lectin galectin-3 interacts with sulfated glycosaminoglycans and chondroitin sulfate proteoglycans. Biochemistry. 2016;55:4541\u201351. doi:\n10.1021\/acs.biochem.6b00504\n\n.","journal-title":"Biochemistry"},{"key":"343_CR80","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1161\/CIRCHEARTFAILURE.113.000846","volume":"7","author":"J Tromp","year":"2014","unstructured":"Tromp J, van der Pol A, Klip IJT, de Boer RA, Jaarsma T, van Gilst WH, et al. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction. Circ Heart Fail. 2014;7:457\u201362. doi:\n10.1161\/CIRCHEARTFAILURE.113.000846\n\n.","journal-title":"Circ Heart Fail"},{"key":"343_CR81","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00441-016-2454-2","volume":"365","author":"IG Lunde","year":"2016","unstructured":"Lunde IG, Herum KM, Carlson CC, Christensen G. Syndecans in heart fibrosis. Cell Tissue Res. 2016;365:539\u201352. doi:\n10.1007\/s00441-016-2454-2\n\n.","journal-title":"Cell Tissue Res"},{"key":"343_CR82","doi-asserted-by":"publisher","unstructured":"Schellings MWM, Vanhoutte D, van Almen GC, Swinnen M, Leenders JJG, Kubben N, et al. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis. Hypertens (Dallas, Tex 1979) 2010;55:249\u201356. doi:\n10.1161\/HYPERTENSIONAHA.109.137885\n\n.","DOI":"10.1161\/HYPERTENSIONAHA.109.137885"},{"key":"343_CR83","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1172\/JCI62423","volume":"122","author":"JK Chan","year":"2012","unstructured":"Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, et al. Alarmins: awaiting a clinical response. J Clin Invest. 2012;122:2711\u20139. doi:\n10.1172\/JCI62423\n\n.","journal-title":"J Clin Invest"},{"key":"343_CR84","doi-asserted-by":"publisher","unstructured":"Nakaya M, Watari K, Tajima M, Nakaya T, Matsuda S, Ohara H, et al. Cardiac myofibroblast engulfment of dead cells facilitates recovery after myocardial infarction. J Clin Invest. 2016:1\u201319. doi:\n10.1172\/JCI83822\n\n.","DOI":"10.1172\/JCI83822"},{"key":"343_CR85","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255\u201365. doi:\n10.1038\/nrcardio.2014.28\n\n.","journal-title":"Nat Rev Cardiol"},{"key":"343_CR86","doi-asserted-by":"publisher","unstructured":"\u2022 van Hout GPJ, Arslan F, Pasterkamp G, Hoefer IE. Targeting danger-associated molecular patterns after myocardial infarction. Expert Opin Ther Targets. 2016;20:223\u201339. doi:\n10.1517\/14728222.2016.1088005\n\n. Comprehensive overview of danger-associated molecular signals in myocardial infarction and their potential utility as therapeutic targets.","DOI":"10.1517\/14728222.2016.1088005"},{"key":"343_CR87","doi-asserted-by":"publisher","unstructured":"Nah D-Y, Rhee M-Y. The inflammatory response and cardiac repair after myocardial infarction. Korean Circ J. 2009;39:393\u20138. doi:\n10.4070\/kcj.2009.39.10.393\n\n.","DOI":"10.4070\/kcj.2009.39.10.393"},{"key":"343_CR88","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ejim.2004.07.013","volume":"15","author":"AS Gabriel","year":"2004","unstructured":"Gabriel AS, Martinsson A, Wretlind B, Ahnve S. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med. 2004;15:523\u20138. doi:\n10.1016\/j.ejim.2004.07.013\n\n.","journal-title":"Eur J Intern Med"},{"key":"343_CR89","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1016\/j.febslet.2006.05.043","volume":"580","author":"PJ Hohensinner","year":"2006","unstructured":"Hohensinner PJ, Kaun C, Rychli K, Ben-Tal Cohen E, Kastl SP, Demyanets S, et al. Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. FEBS Lett. 2006;580:3532\u20138. doi:\n10.1016\/j.febslet.2006.05.043\n\n.","journal-title":"FEBS Lett"},{"key":"343_CR90","doi-asserted-by":"publisher","first-page":"H2221","DOI":"10.1152\/ajpheart.01050.2008","volume":"295","author":"WN Dur\u00e1n","year":"2008","unstructured":"Dur\u00e1n WN. The double-edge sword of TNF-alpha in ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2008;295:H2221\u20132. doi:\n10.1152\/ajpheart.01050.2008\n\n.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"343_CR91","doi-asserted-by":"publisher","unstructured":"\u2022 Yang M, Chen J, Zhao J, Meng M. Etanercept attenuates myocardial ischemia\/reperfusion injury by decreasing inflammation and oxidative stress. PLoS One. 2014;9:e108024. doi:\n10.1371\/journal.pone.0108024\n\n. The cytokine hypothesis was silenced after neutral RCTs with anti-TNF alpha agents, but this article and others keep the hypothesis alive.","DOI":"10.1371\/journal.pone.0108024"},{"key":"343_CR92","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1096\/fj.03-0331fje","volume":"17","author":"M Fuchs","year":"2003","unstructured":"Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, Klein G, et al. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J. 2003;17:2118\u201320. doi:\n10.1096\/fj.03-0331fje\n\n.","journal-title":"FASEB J"},{"key":"343_CR93","doi-asserted-by":"publisher","first-page":"e0167195","DOI":"10.1371\/journal.pone.0167195","volume":"11","author":"MHT Hartman","year":"2016","unstructured":"Hartman MHT, Vreeswijk-Baudoin I, Groot HE, van de Kolk KWA, de Boer RA, Mateo Leach I, et al. Inhibition of interleukin-6 receptor in a murine model of myocardial ischemia-reperfusion. PLoS One. 2016;11:e0167195. doi:\n10.1371\/journal.pone.0167195\n\n.","journal-title":"PLoS One"},{"key":"343_CR94","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.111.243162","volume":"110","author":"NG Frangogiannis","year":"2012","unstructured":"Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159\u201373. doi:\n10.1161\/CIRCRESAHA.111.243162\n\n.","journal-title":"Circ Res"},{"key":"343_CR95","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1161\/ATVBAHA.112.300310","volume":"32","author":"W Chen","year":"2012","unstructured":"Chen W, Saxena A, Li N, Sun J, Gupta A, Lee D-W, et al. Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fibroblasts. Arterioscler Thromb Vasc Biol. 2012;32:2598\u2013608. doi:\n10.1161\/ATVBAHA.112.300310\n\n.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"343_CR96","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejphar.2015.06.025","volume":"763","author":"WC Meijers","year":"2015","unstructured":"Meijers WC, van der Velde AR, Pascual-Figal DA, de Boer RA. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol. 2015;763:115\u201321. doi:\n10.1016\/j.ejphar.2015.06.025\n\n.","journal-title":"Eur J Pharmacol"},{"key":"343_CR97","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cardiores.2006.10.002","volume":"74","author":"M Bujak","year":"2007","unstructured":"Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184\u201395. doi:\n10.1016\/j.cardiores.2006.10.002\n\n.","journal-title":"Cardiovasc Res"},{"key":"343_CR98","doi-asserted-by":"publisher","unstructured":"\u2022 Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction\u2014from repair and remodeling to regeneration. Cell Tissue Res. 2016;365:563\u201381. doi:\n10.1007\/s00441-016-2431-9\n\n. State-of-the-art review on the complex sequelae of events postmyocardial infarction.","DOI":"10.1007\/s00441-016-2431-9"},{"key":"343_CR99","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","volume":"101","author":"MG Sutton","year":"2000","unstructured":"Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981\u20138. doi:\n10.1161\/01.CIR.101.25.2981\n\n.","journal-title":"Circulation"},{"key":"343_CR100","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.molmed.2012.05.005","volume":"18","author":"MF Corsten","year":"2012","unstructured":"Corsten MF, Schroen B, Heymans S. Inflammation in viral myocarditis: friend or foe? Trends Mol Med. 2012;18:426\u201337. doi:\n10.1016\/j.molmed.2012.05.005\n\n.","journal-title":"Trends Mol Med"},{"key":"343_CR101","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Lindner D, Li J, Savvatis K, Klingel K, Blankenberg S, Tsch\u00f6pe C, et al. Cardiac fibroblasts aggravate viral myocarditis: cell specific coxsackievirus B3 replication. Mediat Inflamm. 2014;2014:519528. doi:\n10.1155\/2014\/519528\n\n. Sustained fibroblast activation may be a culprit in myocarditis.","DOI":"10.1155\/2014\/519528"},{"key":"343_CR102","doi-asserted-by":"publisher","first-page":"20446","DOI":"10.1073\/pnas.0810372105","volume":"105","author":"H Negishi","year":"2008","unstructured":"Negishi H, Osawa T, Ogami K, Ouyang X, Sakaguchi S, Koshiba R, et al. A critical link between toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A. 2008;105:20446\u201351. doi:\n10.1073\/pnas.0810372105\n\n.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"343_CR103","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/6543","volume":"5","author":"C Badorff","year":"1999","unstructured":"Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5:320\u20136. doi:\n10.1038\/6543\n\n.","journal-title":"Nat Med"},{"key":"343_CR104","doi-asserted-by":"publisher","unstructured":"Wang Q, Wehrens XHT. Connecting enterovirus infection to dystrophin dysfunction in dilated cardiomyopathy. Ann Transl Med 2016;4:S23. doi:\n10.21037\/atm.2016.10.06\n\n.","DOI":"10.21037\/atm.2016.10.06"},{"key":"343_CR105","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.4049\/jimmunol.170.9.4731","volume":"170","author":"D Fairweather","year":"2003","unstructured":"Fairweather D, Yusung S, Frisancho S, Barrett M, Gatewood S, Steele R, et al. IL-12 receptor beta 1 and toll-like receptor 4 increase IL-1 beta- and IL-18-associated myocarditis and coxsackievirus replication. J Immunol. 2003;170:4731\u20137. doi:\n10.4049\/jimmunol.170.9.4731\n\n.","journal-title":"J Immunol"},{"key":"343_CR106","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Zhao Z, Cai T-Z, Lu Y, Liu W-J, Cheng M-L, Ji Y-Q. Coxsackievirus B3 induces viral myocarditis by upregulating toll-like receptor 4 expression. Biochemistry (Mosc). 2015;80:455\u201362. doi:\n10.1134\/S0006297915040094\n\n. Article on the central role of innate immunity in myocarditis.","DOI":"10.1134\/S0006297915040094"},{"key":"343_CR107","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1161\/CIRCRESAHA.109.195230","volume":"105","author":"K Li","year":"2009","unstructured":"Li K, Xu W, Guo Q, Jiang Z, Wang P, Yue Y, et al. Differential macrophage polarization in male and female BALB\/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res. 2009;105:353\u201364. doi:\n10.1161\/CIRCRESAHA.109.195230\n\n.","journal-title":"Circ Res"},{"key":"343_CR108","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s000590050013","volume":"25","author":"PL Schwimmbeck","year":"2000","unstructured":"Schwimmbeck PL, Rohn G, Wrusch A, Schulze K, Doerner A, Kuehl U, et al. Enteroviral and immune mediated myocarditis in SCID mice. Herz. 2000;25:240\u20134. doi:\n10.1007\/s000590050013\n\n.","journal-title":"Herz"},{"key":"343_CR109","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2353\/ajpath.2008.070207","volume":"172","author":"D Cihakova","year":"2008","unstructured":"Cihakova D, Barin JG, Afanasyeva M, Kimura M, Fairweather D, Berg M, et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol. 2008;172:1195\u2013208. doi:\n10.2353\/ajpath.2008.070207\n\n.","journal-title":"Am J Pathol"},{"key":"343_CR110","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1161\/CIRCULATIONAHA.108.845792","volume":"123","author":"MH Drazner","year":"2011","unstructured":"Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327\u201334. doi:\n10.1161\/CIRCULATIONAHA.108.845792\n\n.","journal-title":"Circulation"},{"key":"343_CR111","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jch.12546","volume":"17","author":"C Bleakley","year":"2015","unstructured":"Bleakley C, Hamilton PK, Pumb R, Harbinson M, McVeigh GE. Endothelial function in hypertension: victim or culprit? J Clin Hypertens (Greenwich). 2015;17:651\u20134. doi:\n10.1111\/jch.12546\n\n.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"343_CR112","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cjca.2016.02.070","volume":"32","author":"A Harvey","year":"2016","unstructured":"Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol. 2016;32:659\u201368. doi:\n10.1016\/j.cjca.2016.02.070\n\n.","journal-title":"Can J Cardiol"},{"key":"343_CR113","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1524-6175.2007.06626.x","volume":"9","author":"J D\u00edez","year":"2007","unstructured":"D\u00edez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich). 2007;9:546\u201350. doi:\n10.1111\/j.1524-6175.2007.06626.x\n\n.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"343_CR114","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00418-008-0541-5","volume":"131","author":"Y Xia","year":"2009","unstructured":"Xia Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis NG. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol. 2009;131:471\u201381. doi:\n10.1007\/s00418-008-0541-5\n\n.","journal-title":"Histochem Cell Biol"},{"key":"343_CR115","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11906-013-0354-3","volume":"15","author":"F Azibani","year":"2013","unstructured":"Azibani F, Fazal L, Chatziantoniou C, Samuel J-L, Delcayre C. Aldosterone mediates cardiac fibrosis in the setting of hypertension. Curr Hypertens Rep. 2013;15:395\u2013400. doi:\n10.1007\/s11906-013-0354-3\n\n.","journal-title":"Curr Hypertens Rep"},{"key":"343_CR116","doi-asserted-by":"publisher","first-page":"H1671","DOI":"10.1152\/ajpheart.00842.2015","volume":"310","author":"\u00c1 Kov\u00e1cs","year":"2016","unstructured":"Kov\u00e1cs \u00c1, F\u00fcl\u00f6p G\u00c1, Kov\u00e1cs A, Cs\u00edp\u0151 T, B\u00f3di B, Priksz D, et al. Renin overexpression leads to increased titin-based stiffness contributing to diastolic dysfunction in hypertensive mRen2 rats. Am J Physiol Heart Circ Physiol. 2016;310:H1671\u201382. doi:\n10.1152\/ajpheart.00842.2015\n\n.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"343_CR117","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13069-015-0023-z","volume":"8","author":"AM Murphy","year":"2015","unstructured":"Murphy AM, Wong AL, Bezuhly M. Modulation of angiotensin II signaling in the prevention of fibrosis. Fibrogenesis Tissue Repair. 2015;8:7. doi:\n10.1186\/s13069-015-0023-z\n\n.","journal-title":"Fibrogenesis Tissue Repair"},{"key":"343_CR118","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Gonz\u00e1lez GE, Rhaleb N-E, D\u2019Ambrosio MA, Nakagawa P, Liu Y, Leung P, et al. Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J Hypertens. 2015;33:144\u201352. doi:\n10.1097\/HJH.0000000000000358\n\n. Article providing interesting data to support a beneficial role for anti-interleukin 6 agents in heart failure.","DOI":"10.1097\/HJH.0000000000000358"},{"key":"343_CR119","doi-asserted-by":"publisher","first-page":"H1287","DOI":"10.1152\/ajpheart.00096.2016","volume":"311","author":"GE Gonz\u00e1lez","year":"2016","unstructured":"Gonz\u00e1lez GE, Rhaleb N-E, D\u2019Ambrosio MA, Nakagawa P, Liao T-D, Peterson EL, et al. Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol. 2016;311:H1287\u201396. doi:\n10.1152\/ajpheart.00096.2016\n\n.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"343_CR120","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jacc.2003.11.058","volume":"43","author":"AR Collins","year":"2004","unstructured":"Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol. 2004;43:1698\u2013705. doi:\n10.1016\/j.jacc.2003.11.058\n\n.","journal-title":"J Am Coll Cardiol"},{"key":"343_CR121","doi-asserted-by":"publisher","unstructured":"Wu Y, Li Y, Zhang C, A X, Wang Y, Cui W, et al. S100a8\/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-induced cardiac inflammation and injury. Hypertens (Dallas, Tex 1979) 2014;63:1241\u201350. doi:\n10.1161\/HYPERTENSIONAHA.113.02843\n\n.","DOI":"10.1161\/HYPERTENSIONAHA.113.02843"},{"key":"343_CR122","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/heart.89.10.1138","volume":"89","author":"C Coletta","year":"2003","unstructured":"Coletta C, Sestili A, Seccareccia F, Rambaldi R, Ricci R, Galati A, et al. Influence of contractile reserve and inducible ischaemia on left ventricular remodelling after acute myocardial infarction. Heart. 2003;89:1138\u201343.","journal-title":"Heart"},{"key":"343_CR123","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution. Eur J Heart Fail. 2016;18:891\u2013975. doi:\n10.1002\/ejhf.592\n\n.","journal-title":"Eur J Heart Fail"},{"key":"343_CR124","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3238\/arztebl.2015.0298","volume":"112","author":"A Hummel","year":"2015","unstructured":"Hummel A, Empe K, D\u00f6rr M, Felix SB. De novo acute heart failure and acutely decompensated chronic heart failure. Dtsch Arztebl Int. 2015;112:298\u2013310. doi:\n10.3238\/arztebl.2015.0298\n\n.","journal-title":"Dtsch Arztebl Int"},{"key":"343_CR125","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijcard.2016.10.038","volume":"226","author":"M Boulogne","year":"2017","unstructured":"Boulogne M, Sadoune M, Launay JM, Baudet M, Cohen-Solal A, Logeart D. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53\u20139. doi:\n10.1016\/j.ijcard.2016.10.038\n\n.","journal-title":"Int J Cardiol"},{"key":"343_CR126","first-page":"30","volume":"52","author":"E Oikonomou","year":"2011","unstructured":"Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. Hell J Cardiol. 2011;52:30\u201340.","journal-title":"Hell J Cardiol"},{"key":"343_CR127","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurjhf\/hfn043","volume":"11","author":"S Heymans","year":"2009","unstructured":"Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119\u201329. doi:\n10.1093\/eurjhf\/hfn043\n\n.","journal-title":"Eur J Heart Fail"},{"key":"343_CR128","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","volume":"119","author":"SA Dick","year":"2016","unstructured":"Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119:159\u201376. doi:\n10.1161\/CIRCRESAHA.116.308030\n\n.","journal-title":"Circ Res"},{"key":"343_CR129","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.ehj.2003.09.022","volume":"24","author":"DJ Grieve","year":"2003","unstructured":"Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage. Eur Heart J. 2003;24:2161\u20133. doi:\n10.1016\/j.ehj.2003.09.022\n\n.","journal-title":"Eur Heart J"},{"key":"343_CR130","doi-asserted-by":"publisher","unstructured":"\u2022 Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263\u201371. doi:\n10.1016\/j.jacc.2013.02.092\n\n. Seminal article proposing a novel paradigm for HFpEF.","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"343_CR131","doi-asserted-by":"publisher","first-page":"e81612","DOI":"10.1371\/journal.pone.0081612","volume":"8","author":"H Zhi","year":"2013","unstructured":"Zhi H, Luptak I, Alreja G, Shi J, Guan J, Metes-Kosik N, et al. Effects of direct renin inhibition on myocardial fibrosis and cardiac fibroblast function. PLoS One. 2013;8:e81612. doi:\n10.1371\/journal.pone.0081612\n\n.","journal-title":"PLoS One"},{"key":"343_CR132","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Mart\u00ednez-Mart\u00ednez E, Calvier L, Fern\u00e1ndez-Celis A, Rousseau E, Jurado-L\u00f3pez R, Rossoni L V., et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertens (Dallas, Tex 1979) 2015;66:767\u201375. doi:\n10.1161\/HYPERTENSIONAHA.115.05876\n\n. Article supporting the potential role of galectin-3 as a therapeutic target in hypertension with excess of aldosterone.","DOI":"10.1161\/HYPERTENSIONAHA.115.05876"},{"key":"343_CR133","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10557-014-6520-2","volume":"28","author":"RA Boer de","year":"2014","unstructured":"de Boer RA, van der Velde AR, Mueller C, van Veldhuisen DJ, Anker SD, Peacock WF, et al. Galectin-3: a modifiable risk factor in heart failure. Cardiovasc Drugs Ther. 2014;28:237\u201346. doi:\n10.1007\/s10557-014-6520-2\n\n.","journal-title":"Cardiovasc Drugs Ther"},{"key":"343_CR134","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/CIRCHEARTFAILURE.112.000129","volume":"6","author":"AR Velde van der","year":"2013","unstructured":"van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219\u201326. doi:\n10.1161\/CIRCHEARTFAILURE.112.000129\n\n.","journal-title":"Circ Heart Fail"},{"key":"343_CR135","doi-asserted-by":"publisher","unstructured":"Meijers WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, Wu AH, Jaffe A, et al. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail. 2016:1\u20139. doi:\n10.1002\/ejhf.669\n\n.","DOI":"10.1002\/ejhf.669"},{"key":"343_CR136","doi-asserted-by":"publisher","unstructured":"\u2022 de Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17:559\u201369. doi:\n10.1002\/ejhf.273\n\n. State-of-the-art review on the current and future role of biomarkers in heart failure management.","DOI":"10.1002\/ejhf.273"},{"key":"343_CR137","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s11897-014-0207-7","volume":"11","author":"AR Velde van der","year":"2014","unstructured":"van der Velde AR, Meijers WC, de Boer RA. Biomarkers for risk prediction in acute decompensated heart failure. Curr Heart Fail Rep. 2014;11:246\u201359. doi:\n10.1007\/s11897-014-0207-7\n\n.","journal-title":"Curr Heart Fail Rep"},{"key":"343_CR138","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00392-012-0500-y","volume":"102","author":"DJ Lok","year":"2013","unstructured":"Lok DJ, Lok SI, Bruggink-Andr\u00e9 de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102:103\u201310. doi:\n10.1007\/s00392-012-0500-y\n\n.","journal-title":"Clin Res Cardiol"},{"key":"343_CR139","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/ejhf.407","volume":"17","author":"WC Meijers","year":"2015","unstructured":"Meijers WC, de Boer RA, van Veldhuisen DJ, Jaarsma T, Hillege HL, Maisel AS, et al. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur J Heart Fail. 2015;17:1271\u201382. doi:\n10.1002\/ejhf.407\n\n.","journal-title":"Eur J Heart Fail"},{"key":"343_CR140","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fphys.2015.00200","volume":"6","author":"ES Lepoj\u00e4rvi","year":"2015","unstructured":"Lepoj\u00e4rvi ES, Piira O-P, P\u00e4\u00e4kk\u00f6 E, Lammentausta E, Risteli J, Miettinen JA, et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 2015;6:200. doi:\n10.3389\/fphys.2015.00200\n\n.","journal-title":"Front Physiol"},{"key":"343_CR141","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12471-010-0007-y","volume":"17","author":"MAGM Olimulder","year":"2009","unstructured":"Olimulder MAGM, van Es J, Galjee MA. The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy. Neth Heart J. 2009;17:481\u20136. doi:\n10.1007\/s12471-010-0007-y\n\n.","journal-title":"Neth Heart J"},{"key":"343_CR142","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacc.2010.11.013","volume":"57","author":"N Mewton","year":"2011","unstructured":"Mewton N, Liu CY, Croisille P, Bluemke D, Lima JAC. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891\u2013903. doi:\n10.1016\/j.jacc.2010.11.013\n\n.","journal-title":"J Am Coll Cardiol"},{"key":"343_CR143","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jacc.2008.06.049","volume":"52","author":"L Iles","year":"2008","unstructured":"Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574\u201380. doi:\n10.1016\/j.jacc.2008.06.049\n\n.","journal-title":"J Am Coll Cardiol"},{"key":"343_CR144","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Papadimitriou L, Smith-Jones PM, Sarwar CMS, Marti CN, Yaddanapudi K, Skopicki HA, et al. Utility of positron emission tomography for drug development for heart failure. Am Heart J. 2016;175:142\u201352. doi:\n10.1016\/j.ahj.2016.02.016\n\n. Molecular imaging, e.g. with PET scanning, holds great promise for early detection, treatment guidance, and other utilities in heart failure management.","DOI":"10.1016\/j.ahj.2016.02.016"},{"key":"343_CR145","doi-asserted-by":"publisher","first-page":"e0165748","DOI":"10.1371\/journal.pone.0165748","volume":"11","author":"N Kashiyama","year":"2016","unstructured":"Kashiyama N, Miyagawa S, Fukushima S, Kawamura T, Kawamura A, Yoshida S, et al. Development of PET imaging to visualize activated macrophages accumulated in the transplanted iPSc-derived cardiac myocytes of allogeneic origin for detecting the immune rejection of allogeneic cell transplants in mice. PLoS One. 2016;11:e0165748. doi:\n10.1371\/journal.pone.0165748\n\n.","journal-title":"PLoS One"},{"key":"343_CR146","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ejhf.62","volume":"16","author":"G Tarone","year":"2014","unstructured":"Tarone G, Balligand J-L, Bauersachs J, Clerk A, De Windt L, Heymans S, et al. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the working group on myocardial function of the European Society of Cardiology. Eur J Heart Fail. 2014;16:494\u2013508. doi:\n10.1002\/ejhf.62\n\n.","journal-title":"Eur J Heart Fail"},{"key":"343_CR147","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/CIRCULATIONAHA.106.644609","volume":"115","author":"D Vanhoutte","year":"2007","unstructured":"Vanhoutte D, Schellings MWM, G\u00f6tte M, Swinnen M, Herias V, Wild MK, et al. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation. 2007;115:475\u201382. doi:\n10.1161\/CIRCULATIONAHA.106.644609\n\n.","journal-title":"Circulation"},{"key":"343_CR148","doi-asserted-by":"publisher","unstructured":"\u2022 Gonz\u00e1lez GE, Cassaglia P, Noli Truant S, Fern\u00e1ndez MM, Wilensky L, Volberg V, et al. Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice. Int J Cardiol. 2014;176:1423\u20135. doi:\n10.1016\/j.ijcard.2014.08.011\n\n. This article describes the potentially adverse effects of early galectin-3 inhibition postmyocardial infarction \u2013 it marks the dangers of interfering with early infarct healing.","DOI":"10.1016\/j.ijcard.2014.08.011"},{"key":"343_CR149","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1056\/NEJM199508033330501","volume":"333","author":"JW Mason","year":"1995","unstructured":"Mason JW, O\u2019Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269\u201375. doi:\n10.1056\/NEJM199508033330501\n\n.","journal-title":"N Engl J Med"},{"key":"343_CR150","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.116.023003","volume":"134","author":"M Methawasin","year":"2016","unstructured":"Methawasin M, Strom JG, Slater RE, Fernandez V, Saripalli C, Granzier H. Experimentally increasing the compliance of titin through RNA binding motif-20 (RBM20) inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction. Circulation. 2016;134:1085\u201399. doi:\n10.1161\/CIRCULATIONAHA.116.023003\n\n.","journal-title":"Circulation"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-017-0343-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-017-0343-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-017-0343-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T02:41:34Z","timestamp":1500950494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-017-0343-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1007\/s11897-017-0343-y","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}